id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-E-2611-0006,FDA,FDA-2023-E-2611,Determination of Regulatory Review Period for Purposes of Patent Extension; AGILI–C,Notice,Determinations,2024-11-19T05:00:00Z,2024,11,2024-11-19T05:00:00Z,2025-01-22T04:59:59Z,2024-11-19T13:37:18Z,2024-26910,0,0,0900006486827d2d
FDA-2023-E-2611-0005,FDA,FDA-2023-E-2611,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2024-11-04T05:00:00Z,2024,11,2024-11-04T05:00:00Z,,2024-11-04T19:20:46Z,,0,0,09000064867edea3
FDA-2023-E-2611-0004,FDA,FDA-2023-E-2611,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T13:29:32Z,,0,0,090000648648be68
FDA-2023-E-2611-0003,FDA,FDA-2023-E-2611,Letter from FDA CDER to U S Patent and TradeMark Office,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T23:54:48Z,,0,0,09000064863ae057